Lazard Portfolio comments in fin review, page-15

I am with you D . Again it is the commutation
from Administration to shareholders which is
forever lacking. The SP is the only indicator
of company. Regarding Myring I don’t believe
we have even resubmitted application to FDA
for the 4th time for approval. Also a generic
mis exactly that Generic. You cannot have
improved generic if your medication is different
it should be submitted to FDA as Stand alone
product. We are according to previously stated
comments spending $75m this year on marketing E4. This is with the representatives
employed In March . You may be onto something regarding Taylor and Kylie. Spend
the money on them and not reps. They well
garner superior marketing penetration.